Corporate Investor

Updated:

Zhejiang Yanglin Biotechnology

Zhejiang Yanglin Biotechnology is a corporate investor based in Hangzhou, China. It focuses on investments in Asia. The firm has committed to one fund.

Zhejiang Yanglin Biotechnology logo

Zhejiang Yanglin Biotechnology

Zhejiang Yanglin Biotechnology is a corporate investor based in Hangzhou, China. It focuses on investments in Asia. The firm has committed to one fund.

General information

Firm type

Corporate Investor

Location

Region

Asia

Country

China

City

Hangzhou

Corporate office

Hangzhou, Zhejiang, China

Principals

Chairman (Name Undisclosed)

Chairman

Sector focus

BiotechnologyHealthcare Services

Frequently asked questions

What investment stages does Zhejiang Yanglin Biotechnology target?

The firm's mandate covers the full venture lifecycle: seed, start-up, expansion, and late-stage venture. This broad stage coverage allows it to support companies from preclinical research through to commercialization. Typical corporate biotech investors in China maintain wide stage flexibility to capture innovation early while reserving capacity for later-stage de-risked assets closer to market.

Is Zhejiang Yanglin Biotechnology structured as a standalone fund or a balance-sheet investor?

The firm operates as a balance-sheet investor, deploying capital directly from its parent company rather than raising discrete funds from external limited partners. This structure gives it permanent capital and removes the fundraising cycle constraints that shape behavior at traditional venture firms, but also limits public transparency since no fund documents are filed with regulators.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Hangzhou Corporate Investor profiles